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Summary
Objective Metformin is widely used for the treatment of type 2
diabetes. Growing evidence supports the beneficial effects of
metformin also in patients with polycystic ovary syndrome
(PCOS). It was recently reported that metformin has a TSH-
lowering effect in hypothyroid patients with diabetes being treated
with metformin.
Design Aim of this study was to evaluate the effect of metformin
treatment on the thyroid hormone profile in patients with PCOS.
Patients and measurements Thirty-three patients with PCOS
were specifically selected for being either treated with levothyroxine
for a previous diagnosis of hypothyroidism (n = 7), untreated sub-
clinically hypothyroid (n = 2) or euthyroid without levothyroxine
treatment (n = 24) before the starting of metformin. The serum
levels of TSH and FT4 were measured before and after a 4-month
period of metformin therapy.
Results Thyroid function parameters did not change after starting
metformin therapy in euthyroid patients with PCOS. In the 9
hypothyroid patients with PCOS, the basal median serum levels of
TSH (3Æ2 mIU/l, range = 0Æ4–7Æ1 mIU/l) significantly (P < 0Æ05)
decreased after a 4-month course of metformin treatment
(1Æ7 mIU/l, range = 0Æ5–5Æ2 mIU/l). No significant change in the
serum levels of FT4 was observed in these patients. The TSH-lower-
ing effect of metformin was not related to the administered dose of
the drug, which was similar in euthyroid as compared with hypo-
thyroid patients with PCOS (1406 ± 589 vs 1322 ± 402 mg/day,
respectively; NS).
Conclusions These results indicate that metformin treatment has
a TSH-lowering effect in hypothyroid patients with PCOS, both
treated with l-thyroxine and untreated.
(Received 13 January 2011; returned for revision 26 January 2011;
finally revised 15 February 2011; accepted 8 March 2011)
Introduction
Metformin is a widely used drug for the treatment of type 2 diabe-
tes. Metformin is commonly regarded as safe drug, because no clin-
ically relevant pharmacologic interaction was described with most
of the commonly used drugs, with the exception of folate and vita-
min B12.1–3 With specific regard to polycystic ovary syndrome
(PCOS), metformin is not licensed for the treatment of this condi-
tion in any country to date.4 Nevertheless, in the last few years,
growing evidence supported beneficial effects of metformin in
PCOS.5,6 These studies prompted consensus statements and rec-
ommendations for the use of metformin in patients with PCOS.7–10
Despite the fact that metformin was introduced nearly 50 years
ago in the clinical practice for the treatment of diabetes, only
recently has this drug was reported to modify the thyroid hormone
profile,11–13 producing a significant decrease in the serum levels of
TSH. Vigersky et al.11 described four patients with primary hypo-
thyroidism, being euthyroid on l-thyroxine (LT4), in whom the
administration of metformin led to a significant fall in the serum
levels of TSH. In these patients, the serum levels of FT4 were
unchanged, and no clinical sign of thyrotoxicosis was observed.
The effect of metformin was found to be reversible, because drug
withdrawal was accompanied by a significant rise in serum TSH
levels, which returned to the premetformin serum concentration.11
More recently, it was demonstrated that the TSH-lowering effect of
metformin is also observed in primary hypothyroid patients with
diabetes and primary hypothyroidism, who are not treated with
L-T4 replacement therapy.13
Despite the clinical relevance of these findings, the mechanisms
by which metformin produces a TSH-lowering effect remain lar-
gely unknown. To further characterise the effect of metformin
treatment on circulating thyroid function parameters, we investi-
gated the impact of metformin treatment on the serum levels of
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thyroid hormones and TSH in a cohort of patients with PCOS,
both euthyroid or hypothyroid.
Patients andmethods
Patients
The original study group included 35 patients with PCOS being
treated with metformin. Among them, seven patients were specifi-
cally selected from the computerized database of our outpatient
clinic for being hypothyroid on l-thyroxine substitution treatment.
They were affected by chronic autoimmune thyroiditis, and their
l-thyroxine substitution dose was stable since at least 6 months.
Twenty-eight more patients with PCOS were consecutively
recruited from our outpatient clinic. Two of them had subclinical
hypothyroidism because of chronic autoimmune thyroiditis and
were left untreated. The remaining 26 patients were euthyroid with
no detectable thyroid disease. Two patients in this group were
excluded from the study during the follow-up: one patient for lack
of compliance to metformin treatment and the other one for hav-
ing missed the scheduled visit plan. Thus, thirty-three patients
(seven hypothyroid being treated with l-thyroxine, two untreated
with subclinical hypothyroidism and 24 euthyroid) completed the
study.
The diagnosis of PCOS was formulated according to the criteria
established by the Rotterdam consensus workshop.14 The mean
(±SD) age of patients with PCOS was 25Æ9 ± 5Æ9 years, and their
mean BMI was 30Æ7 ± 4Æ2 Kg/m2. The mean daily dose of metfor-
min in the whole study group was 1Æ383 ± 539 mg.
Body mass index (BMI) and serum FT4, FT3, TSH were evaluated
before and 4 months after starting metformin treatment. Blood
samples for assaying FT4, FT3 and TSH were drawn between 08:00
and 09:00 a.m., after an overnight fast. BMI was calculated as the
weight (kg) divided by the square of height (m). All subjects gave
their informed consent to be included into the study, which was
performed in accordance with the guidelines proposed in the
Declaration of Helsinki.
Serum assays
Serum concentrations of free triiodothyronine (FT3, normal range
3Æ7–7Æ2 pmol/l), free thyroxine (FT4, normal range 9Æ0–23Æ2 pmol/
l) and thyroid-stimulating hormone (TSH, normal range 0Æ4–
4Æ0 mIU/l) were measured using immune-chemiluminescent assays
by an automated analyser (Immulite 2000; DPC Cirrus, Los Ange-
les, CA, USA) employing commercially available kits (all from
Diagnostic Products Corporation, Los Angeles, CA, USA). In these
assays, the intra-assay coefficient of variation ranged from 4Æ3% to
8Æ4% for FT3, from 5Æ2% to 7Æ5% for FT4 and from 5Æ1% to 12Æ5%
to for TSH. The interassay coefficient of variation ranged from
5Æ4% to 10Æ0% for FT3, from 7Æ7% to 9Æ0% for FT4 and from 6Æ4%
to 12Æ5% 6Æ4% for TSH. The analytical sensitivities were
1Æ54 pmol/l for FT3, 3Æ9 pmol/l for FT4 and 0Æ004 mIU/l for TSH
(Third-generation TSH assay). Samples were assayed in duplicate.
Quality control pools at low, normal and high concentrations for
all parameters were present in each assay, respectively.
Statistical analysis
Statistical analysis was performed using SPSS software (SPSS, Inc.,
Evanston, IL, USA). All comparisons between groups were per-
formed by Student’s t test for unpaired data and Mann–Whitney U
test according to the parametric or nonparametric distribution of
data. Owing to the nonparametric distribution of the data, pre-
treatment and on-treatment results were compared by Wilcoxon
test. A P-value <0Æ05 was considered statistically significant.
Results
When patients with PCOS were evaluated as a whole group, no sig-
nificant change in the serum concentrations of FT4 and TSH was
observed by comparing data found before and after the 4-month
course of metformin treatment. However, when hormone data
from euthyroid and hypothyroid (either treated or untreated with
l-thyroxine) patients with PCOS were evaluated separately, a dif-
ferent picture emerged. In the twenty-four euthyroid patients with
PCOS, the median serum levels of TSH before starting metformin
were 1Æ4 mIU/l (range = 0Æ4–3Æ8 mIU/l) and did not significantly
change after a 4-month course of metformin: 1Æ6 mIU/l (ran-
ge = 0Æ4–3Æ7 mIU/l). Similarly, the median serum levels of FT4
did not significantly change being 15Æ9 pmol/l (range = 12Æ6–19Æ3
pmol/l) before starting metformin and 16 pmol/l (range = 14–
19Æ3 pmol/l) after a 4-month course of the drug. In the nine hypo-
thyroid patients with PCOS, either treated with l-thyroxine
or untreated, the median pretreatment serum levels of TSH
(3Æ2 mIU/l, range = 0Æ4–7Æ1 mIU/l) significantly decreased after a
4-month course of metformin (1Æ7 mIU/l, range = 0Æ5–5Æ2 mIU/l)
(P < 0Æ05). The individual plots of serum TSH concentrations in
the nine hypothyroid patients before and after metformin treat-
ment are shown in Fig. 1. In these patients, no significant change in
the median serum levels of FT4 before (15Æ9 pmol/l, range = 11Æ6–
18Æ0 pmol/l) and after (15Æ9 pmol/l, range = 11Æ3–17Æ9 pmol/l) the
4-month course of metformin treatment was observed. None of
our patient with PCOS and hypothyroidism experienced a sup-
pressed TSH during metformin treatment.
Fig. 1 Individual plots of serum TSH concentrations before and 4 months
after starting metformin treatment in hypothyroid patients with polycystic
ovary syndrome.
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Clinical and anthropometric findings did not significantly differ
when comparing the 24 euthyroid PCOS patients with the nine
hypothyroid ones. In particular, no significant difference emerged
regarding median age and in BMI. More interestingly, no signifi-
cant difference as to the mean administered dose of metformin was
found between the 24 euthyroid and the nine hypothyroid patients
with PCOS (1322 ± 402 mg vs 1406 ± 589, respectively). During
metformin treatment, no significant change in the mean BMI score
was observed, both in the 24 euthyroid patients (pretreat-
ment = 31Æ0 ± 4Æ2 Kg/m2; posttreatment = 30Æ1 ± 3Æ7 Kg/m2)
and in the nine hypothyroid (pretreatment = 29Æ9 ± 4Æ6 Kg/m2,
posttreatment = 29Æ5 ± 4Æ4 Kg/m2) patients with PCOS.
Discussion
Treatment with metformin in euthyroid patients with PCOS is not
associated with significant changes in the serum levels of TSH and
FT4. On the other hand, metformin treatment results in a signifi-
cant reduction in serum TSH concentrations in hypothyroid
patients with PCOS, independently from the concomitant substitu-
tion therapy with l-thyroxine.
Previous studies reported a significant fall in serum TSH con-
centrations and a slight, even if not significant, increase in serum
FT4 values following initiation of metformin therapy in patients
with diabetes and hypothyroidism either treated with l-thyroxine
or untreated.11–13 The mechanisms by which metformin would
lead to a lowering of serum TSH levels are still debated. Several
mechanisms have hypothesized for explaining this phenomenon:
i) a change in the affinity or in the number of TSH receptors; ii)
an increase in the central dopaminergic tone; or iii) a direct effect
of metformin on TSH regulation. The design of the current study
does not allow conclusions to be drawn in this regard, neverthe-
less the observation that metformin has a TSH-lowering effect
also in patients with PCOS and hypothyroidism seems relevant.
In particular, the observation that this TSH-lowering effect of
metformin also occurs in untreated hypothyroid patients excludes
that the effect is because of increased absorption of L-T4 in the
gastrointestinal tract. Neither can the TSH-lowering effect be
ascribed to the dose of metformin, which was similar in euthy-
roid as compared with hypothyroid patients with PCOS. More-
over, our findings in euthyroid patients with diabetes13 and
PCOS, and those reported by Oleandri et al.,15 showing no
change of serum thyroid hormones and TSH levels in euthyroid
patients with abdominal obesity after 3 months of metformin
therapy, would not be in line with the previously hypothesized
direct effect of metformin on TSH regulation. Taken together,
our results have not disclosed the precise mechanism by which
metformin exerts its ‘‘thyroid effect’’, but provide further insights
for future investigations.
The amelioration of thyroid function in PCOS patients with sub-
clinical hypothyroidism following initiation of metformin treat-
ment might also be viewed as an adjunctive mechanism by which
metformin has beneficial effects in this condition. It is known that
hypothyroidism may worsen PCOS by further decreasing the levels
of sex hormone–binding globulin and by increasing the conversion
of androstenedione to testosterone and its aromatization to oestra-
diol.16,17 Thus, correction of hypothyroidism might be helpful for
the management of PCOS. If future studies enrolling larger series
of patients with PCOS will confirm our observation, a further step
in our understanding of the beneficial effect of metformin in these
patients might be performed.
In conclusion, the results of this study show that treatment with
metformin in hypothyroid patients with PCOS leads to a signifi-
cant decrease in the serum levels of TSH. No such effect is observed
in euthyroid patients with PCOS. This observation seems of clinical
relevance. Indeed, as stated by Haugen in his recent review, metfor-
min may affect thyroid function tests and TSH levels in hypothy-
roid patients.18 Thus, monitoring serum TSH and free T4 levels is
recommended in patients taking both metformin and l-thyroxine.
Our results extend the observations of the TSH-lowering effect of
metformin, previously described only in hypothyroid patients with
diabetes, also to hypothyroid patients with PCOS.
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